Συνιστώμενη δοσολογία SPERMOTREND
Μία κάψουλα 2 φορές ημερησίως.
Προειδοποιήσεις
Τα συμπληρώματα διατροφής δεν πρέπει να χρησιμοποιούνται ως υποκατάστατο μιας ισορροπημένης δίαιτας. Τα συμπληρώματα διατροφής δεν προορίζονται για πρόληψη, αγωγή, θεραπεία ανθρώπινης νόσου. Μην υπερβαίνετε την ημερήσια δοσολογία. Κρατείστε το μακριά από παιδιά.
Συστατικά ανά 1 κάψουλα:
Fructose 104 mg
African Plum Extract (Pygeum africanum Hook. f.) 100 mg
Maltodextrin 89 mg
L-Carnitine Fumarate 70,5 mg
L-Arginine 50 mg
Microcrystalline cellulose 50 mg
Vitamine C (L-Ascorbic Acid) 30 mg
Vitamine E (DL-alpha-tocopheryl acetate) 22 mg
Zinc Sulfate 20 mg
Vitamin B6 (Pyridoxine hydrochloride) 1 mg
Folic Acid (Pteroylmonoglutamic acid) 0,1 mg
Sodium Selenite 0,02 mg
Vitamine B12 (Cyanocobalamin) 0,0005 mg
Abstract Κλινικής Μελέτης Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης
From 2019 until 2022, 79 infertile men, with at least one pathological variable in semen analysis (concentration, motility, morphology) according to the World Health Organization (WHO) 2010 criteria, were randomized to either oral antioxidant supplementation (n = 40) or placebo (n = 39) for three consecutive months.
The study was conducted at the Unit for Human Reproduction of the 1st Department of Obstetrics and Gynecology at Aristotle University of Thessaloniki in collaboration with the private andrology diagnostic center of Mrs Th. Zeginiadou (Andrologylab). The study was approved by the Ethics Committee Review Board of Aristotle University of Thessaloniki. Written consent was obtained from all patients. Sperm samples were evaluated according to WHO criteria for semen variables, DFI and for levels of ROS. Evaluation took place before the initiation of treatment with either antioxidants or placebo and after its discontinuation, three months later.
Sperm progressive motility significantly increased in the antioxidant group after three months of treatment (1%, 95%CI: 0 to +2, p=0.037), while this was not the case in the placebo group (0%, 95%CI: -0.2 to +3, p=0.057).
Similarly, DFI significantly decreased in the antioxidant group after three months of treatment (-4%, 95%CI: -6 to -1.7, p=0.007), while this was not the case in the placebo group (-1% 95%CI: -4 to +1, p=0.126).
Although, no statistically significant differences were observed in the changes of pre and post treatment values, between oral antioxidants and placebo, a modest improvement in progressive motility and DFI, was present in the oral antioxidant but not in the placebo group, after a three-month treatment period. Whether, these findings are of clinical importance might be examined in future studies.